Lumos Pharma, Inc. (LUMO)
- Previous Close
4.3500 - Open
4.3400 - Bid --
- Ask --
- Day's Range
4.3100 - 4.4600 - 52 Week Range
1.3700 - 4.5800 - Volume
135,231 - Avg. Volume
96,329 - Market Cap (intraday)
35.828M - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-4.4200 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.69
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
lumos-pharma.comRecent News: LUMO
View MorePerformance Overview: LUMO
Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUMO
View MoreValuation Measures
Market Cap
35.34M
Enterprise Value
18.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.70
Price/Book (mrq)
3.44
Enterprise Value/Revenue
12.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-60.50%
Return on Equity (ttm)
-132.56%
Revenue (ttm)
1.49M
Net Income Avi to Common (ttm)
-35.75M
Diluted EPS (ttm)
-4.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
16.8M
Total Debt/Equity (mrq)
4.37%
Levered Free Cash Flow (ttm)
-22.13M
Research Analysis: LUMO
View MoreCompany Insights: LUMO
LUMO does not have Company Insights